ArticleKidney3602020
Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes.
Open access · diamondAbstract readValidation Study
In one paragraph
Article in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Artificial intelligence in nephrology: predicting CKD progression and personalizing treatment.International urology and nephrology · 2026Review
- Dynamic Bayesian networks to predict loss of kidney function: a cross-institution use case in a large cohort with or at-risk of CKD.BMC medical informatics and decision making · 2026Article
- Interpretable predictive model for deterioration of kidney function in patients with stage 4 cardiovascular-kidney-metabolic syndrome.BMC nephrology · 2026Article
- Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population.Kidney medicine · 2026Article
- The lipid-podocyte axis: emerging clues in membranous nephropathy pathogenesis.Frontiers in medicine · 2026Review
- kidneyintelX.dkd: An Innovation in Precision Medicine for Diabetic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2025Article
- Risk of Progression and Costs of Care for Patients with Type 2 Diabetes and Chronic Kidney Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- The New Horizon: A Viewpoint of Novel Drugs, Biomarkers, Artificial Intelligence, and Self-Management in Improving Kidney Transplant Outcomes.Journal of clinical medicine · 2025Article
- Role of Artificial Intelligence in Nanomedicine and Organ-specific Therapy: An Updated Review.Current drug targets · 2025Review
- Artificial Intelligence in Nephrology: Clinical Applications and Challenges.Kidney medicine · 2025Review
- Classification and Regression Trees analysis identifies patients at high risk for kidney function decline following hospitalization.PloS one · 2025Article
- Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.Frontiers in endocrinology · 2025Review
- The Use of Deep Learning and Machine Learning on Longitudinal Electronic Health Records for the Early Detection and Prevention of Diseases: Scoping Review.Journal of medical Internet research · 2024Article
- External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance.Frontiers in endocrinology · 2024Observational
- The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease.Kidney360 · 2022Article
- Cohort design and natural language processing to reduce bias in electronic health records research.NPJ digital medicine · 2022Article
- Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation.FEBS letters · 2022Review
- Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.Diabetologia · 2021Observational
- Artificial intelligence enabled applications in kidney disease.Seminars in dialysis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Kinsuk ChauhanDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-1198-3562
Girish N NadkarniDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Fergus FlemingRenalytixAI, New York, New York.
James McCulloughRenalytixAI, New York, New York.
Cijiang J HeDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
John QuackenbushDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Barbara MurphyDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Michael J DonovanDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York.
Steven G CocaDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Joseph V BonventreRenal Division, Brigham and Women's Hospital, Boston, Massachusetts.
Icahn School of Medicine at Mount Sinai · USBrigham and Women's Hospital · USHarvard University · US
Funding
Incorporating genomics into the clinical care of diverse NYC childrenU01HG009610 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELB, BRUCE D, HOROWITZ, CAROL R · 2017 to 2021
$17.0MNovel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3MKIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6MMulti-Omics and Chronic Kidney Disease: Correlation with HistologyR01DK108803 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Morgan Erika Grams, EUGENE P. RHEE · 2016 to 2026
$6.4MGenomic Medicine Pilot For Hypertension And Kidney Disease In Primary CareU01HG007278 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOROWITZ, CAROL R · 2013 to 2018
$5.7MMechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2MPlasminogen in glomerular disease progressionR01DK126477 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Kirk N Campbell · 2020 to 2026
$3.8MNovel serum and urinary biomarkers of diabetic kidney diseaseR01DK096549 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2012 to 2016
$2.9MNorth East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical CenterU01DK116100 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Darshana Dadhania, Samira Farouk · 2017 to 2026
$2.5MImpact of Exercise on Kidney Function and Injury among Elders in the LIFE TrialR01DK115562 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI COCA, STEVEN G, SHLIPAK, MICHAEL G · 2018 to 2020
$2.2MImpact of early antiretroviral therapy on kidney disease outcomesR01DK112258 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WYATT, CHRISTINA M · 2017 to 2021
$2.1MLeveraging Clinical Trials of Diabetic Kidney Disease to Advance BiomarkersU01DK106962 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G, PARIKH, CHIRAG R · 2015 to 2019
$1.3MNHGRI NIH HHS U01 HG007278NHGRI NIH HHS U01 HG009610NHLBI NIH HHS R01 HL085757NIDDK NIH HHS K23 DK107908NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R01 DK096549NIDDK NIH HHS R01 DK108803NIDDK NIH HHS R01 DK112258NIDDK NIH HHS R01 DK115562NIDDK NIH HHS R01 DK126477NIDDK NIH HHS R37 DK039773NIDDK NIH HHS U01 DK106962NIDDK NIH HHS U01 DK116100NIOSH CDC HHS U01 OH011326
Abstract
Background: Individuals with type 2 diabetes (T2D) or the apolipoprotein L1 high-risk ( Methods: We selected two cohorts from the Mount Sinai Bio Results: Overall, 23% of those with T2D and 18% of those with Conclusions: In patients with T2D or
Indexed as
Diabetes Mellitus, Type 2Electronic Health RecordsApolipoprotein L1BiomarkersGlomerular Filtration RateHumansKidneyMachine LearningPrognosisAPOL1 protein, humanApolipoprotein L1BiomarkersAPOL1 proteinapolipoprotein L1area under curvebiologic specimen banksclinical nephrologydiabetes mellituselectronic health recordsfollow-up studiesglomerular filtration rateHAVCR1 proteinhepatitis A virus cellular receptor 1humanprognosisreceptorsTNFRSF1A proteintumor necrosis factortumor necrosis factorstype 2type I
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.